Analysts expect Bio-Rad Laboratories, Inc. to report revenue of 653.25 M for Q4 26, against a range of 613.64 M to 692.86 M. The most recent reported quarter, Q3 26, came in at 656.40 M, a 4.5% beat against the 627.88 M consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 667.50 M | 585.40 M | 651.60 M | 653.00 M | 693.20 M | 592.10 M | 651.00 M | 656.40 M | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 683.42 M | 583.73 M | 625.33 M | 717.77 M | 788.76 M | 661.80 M | 674.34 M | 660.13 M | 692.86 M | 684.99 M | 729.03 M | 750.02 M | 722.79 M | 641.54 M | 721.46 M | 720.43 M | |||||||||
| Low Estimate | 602.74 M | 512.44 M | 576.66 M | 656.04 M | 669.07 M | 578.13 M | 622.33 M | 595.62 M | 613.64 M | 562.76 M | 675.29 M | 650.13 M | 651.67 M | 551.85 M | 600.60 M | 602.22 M | |||||||||
| Consensus Estimate | 643.08 M | 548.09 M | 600.99 M | 686.91 M | 728.91 M | 619.97 M | 648.33 M | 627.88 M | 653.25 M | 623.88 M | 702.16 M | 700.07 M | 687.23 M | 596.69 M | 661.03 M | 661.33 M |
Analysts expect Bio-Rad Laboratories, Inc. to report earnings per share of 2.91 for Q4 26, against a range of 2.79 to 3.03. The most recent reported quarter, Q3 26, came in at 2.65, a 12.3% beat against the 2.36 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 2.90 | 2.54 | 2.61 | 2.26 | 2.51 | 1.89 | 2.62 | 2.65 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 3.08 | 1.85 | 1.78 | 1.96 | 2.92 | 2.13 | 2.00 | 2.59 | 3.03 | 2.84 | 2.58 | 2.58 | 3.23 | 3.37 | 3.08 | 3.01 | |||||||||
| Low Estimate | 2.80 | 1.61 | 1.60 | 1.68 | 2.74 | 1.97 | 1.66 | 2.13 | 2.79 | 2.60 | 2.36 | 2.36 | 2.73 | 2.85 | 2.88 | 2.57 | |||||||||
| Consensus Estimate | 2.94 | 1.73 | 1.69 | 1.82 | 2.83 | 2.05 | 1.83 | 2.36 | 2.91 | 2.72 | 2.47 | 2.47 | 2.98 | 3.11 | 2.98 | 2.79 |
Pull Wall Street consensus for Bio-Rad Laboratories, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=BIO&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "BIO", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=BIO&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();